# A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

> **NCT04254783** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 20 (actual)

## Conditions studied

- Ulcerative Colitis (UC)
- Crohn's Disease

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Cytochrome P450 (CYP) Substrates

## Key facts

- **NCT ID:** NCT04254783
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-27
- **Primary completion:** 2022-10-14
- **Final completion:** 2022-10-14
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04254783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04254783, "A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04254783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*